DYADIC INTERNATIONAL | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (27)

View All

Latest Posts

About This Stock More About This Stock
Week In Review: RemeGen Out-Licenses Rights For HER2 ADC To Seagen In $2.6 Billion Deal
Article By: ChinaBio® Today
Saturday, August 14, 2021 1:30 PM EDT
Yantai's RemeGen out-licensed global rights (ex-Asia) for its novel HER2-targeted ADC to Seagen in a $2.6 billion deal. Seagen, an antibody conjugate company, will pay $200 million upfront and up to $2.4 billion in milestones.
In this article: DYAI, SRNE, SGEN, CHRS, EPZM, HCM, 1801.HK, 1877.HK, 9995.HK, PHAS
Read
PLX Upcoming Volatility Creates Opportunity
Article By: Moon Kil Woong
Tuesday, July 27, 2021 9:01 AM EDT
PLX was up on FDA notice last year on a CRL postponement that its PDUFA review of PRX-102. In the meantime, phase III trials continue to provide more positive results. It is a stock worth watching.
In this article: PLX Also: INO, DYAI, BCLI, LFMD
Read
Stock Charts To Watch - Monday, June 22
Video By: Harry Boxer
Tuesday, June 23, 2020 8:57 PM EDT
Dyadic International, Inc. broke out of a wedge on Monday, and jumped 1.21, or 13.4%, to 10.26, 658,565 shares traded.
In this video: DYAI, OSTK, NK, WKHS, ALT, IDEX
Watch
Stock Charts To Watch - Wednesday, June 10
Video By: Harry Boxer
Wednesday, June 10, 2020 9:12 PM EDT
Bloom Energy Corporation popped on Wednesday and exploded for 1.87, or 22%, to 10.27, after reaching a session high of 10.50, on 9.6 million shares traded.
In this video: DYAI, CLDX, BE, OSTK, PAAS
Watch
All Posts

Latest Tweets for $DYAI

No tweets yet!

PARTNER HEADLINES

$DYAI

Comments Status Updates
This Vaccine Stock Is Now On Janssen Pharmaceuticals, J&J, The White House's Radar
Andrew Armstrong • 1/4/2022 7:02:12 PM

Oh man, sorry to hear about your cancer Brett Hershman.

Personally, I'd like to hear more about $DYAI.
1 to 1 of 1 comments